Investor FAQ

When was Taro established?

The legal and commercial name of the company is Taro Pharmaceutical Industries Ltd. Taro was founded in Israel in 1950 and incorporated under the laws of the State of Israel in 1959. The Company expanded into Canada in 1984, and the U.S. in 1988. North America represents more than 90% of Taro’s sales.

What is Taro's corporate address?

Taro Pharmaceutical Industries Ltd.
14 Hakitor Street
Haifa Bay 2624761 Israel

What are the addresses of your major facilities?

Taro Pharmaceutical Industries Ltd. (Taro Israel)
14 Hakitor Street
Haifa Bay 2624761 Israel

Taro Pharmaceuticals U.S.A., Inc. (Taro USA)
3 Skyline Drive
Hawthorne, NY 10532 USA

Taro Pharmaceuticals, Inc. (Taro Canada)
130 East Drive
Brampton, Ontario L6T 1C1, Canada

Where are Taro’s shares listed?

Since March 22, 2012, our ordinary shares have been traded on the NYSE under the symbol “TARO.”

How can I purchase shares of Taro stock?

Taro stock can be purchased through any brokerage firm. Taro does not have a Direct Stock Purchase Program.

Who is Taro’s transfer agent?

American Stock Transfer
New York, NY USA
www.astfinancial.com
(800) 937-5449 or (718) 921-8124

What can the transfer agent help me with?

Taro’s Transfer Agent can assist with any of the following issues:

Lost stock certificates
Clarification of number of shares owned
Transfer of certificates between individuals
Transfer of certificates to/from broker
Address changes
Other stock related matters

Does Taro pay a dividend?

On November 5, 2018, the Taro Board of Directors declared a $500 million ($12.86 per share) Special Cash Dividend which was paid on December 28, 2018, to shareholders of record at the close of business on December 11, 2018. Taro does not pay a regular cash dividend.

Where can I find historical prices for Taro’s common stock?

Use the Historical Price Lookup feature under Stock Information within the Investor Relations section of this website. You can also obtain a Stock Quote or a Stock Chart, which provides stock prices and volume trends over selected periods, within the Stock Information section.

How can I receive a hard copy of Taro's complete audited financial statements?

Taro provides all shareholders, upon request, with a hard copy of our complete audited financial statements on Form 20-F- free of charge. Investor Relations Contact

The Annual Report on Form 20-F is also available on Taro’s website. (Click here)

How can I receive investor materials as they are issued?

Click here to be added to our mailing list.

How do I contact Taro Investor Relations?

Taro Pharmaceuticals U.S.A., Inc.
3 Skyline Drive
Hawthorne, NY 10532
Phone: (914) 345 9001
investorrelations@taro.com

How can I receive a copy of your product list?

You can request a product list in the way that’s most convenient for you:

Use the online product list for the country you're interested in, then click on "Taro Products"
Call 1-888-TARO-USA
Write to us, c/o Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Drive, Hawthorne, NY 10532, Attn: Marketing, Product list-Request

What percentage of Taro does Sun Pharmaceuticals own?

As of December 31, 2019, Sun Pharmaceutical Industries Ltd., and its affiliates ("Sun"), control 77.1% of our outstanding ordinary shares and 100% of our founders' shares, therefore, Sun controls 84.7% of the voting power in Taro.

Who do you consider as major competitors in your major markets?

In Israel, we compete with Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexcel Pharma Israel, and Rafa Laboratories Ltd., among others. In addition, many leading multinational companies, including Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc., market their products in Israel.

In the United States, we compete with branded pharmaceutical manufacturers such as Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Valeant Pharmaceuticals International, Inc. and Galderma Laboratories, LP., as well as with generic companies such as Teva Pharmaceuticals U.S.A., Mylan Inc., Perrigo Company PLC, Glenmark Generics, Inc., USA., PruGen Inc. and Sandoz Pharmaceuticals (the generics subsidiary of Novartis).

In Canada, our competition includes Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Valeant Canada, AstraZeneca Canada, Johnson & Johnson Inc., Bayer Inc. and Bristol-Myers Squibb Canada. We also compete with other manufacturers of generic products, such as Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated and Pharmascience Inc.

What is Taro’s fiscal year?

Taro’s fiscal year runs from April 1 to March 31.

Can individual investors listen to the earnings conference call with analysts?

Yes, Taro's earnings conference calls, which are held on a semi-annual basis, are audio webcast live. Transcripts of the recent earnings conference calls are on this website. (Click here)

Does Taro issue quarterly reports?

Taro issues a quarterly Earnings Press Release and files these financial reports on Form 6-K with the SEC. You can find copies of recent reports on our website (Click here).

Who are the members of Taro’s Board of Directors?

For a list of our Board members, (Click here).